Aurinia Pharmaceuticals Inc.
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $83.2M | $77.7M | $77.1M | $73.5M | $70.0M | $62.5M | $59.9M | $67.8M |
| Cost of Revenue | $6.6M | $6.5M | $8.8M | $8.2M | $7.1M | $8.6M | $5.6M | $6.0M |
| Gross Profit | $76.7M | $71.2M | $68.3M | $65.3M | $62.9M | $53.9M | $54.3M | $61.7M |
| Gross Margin | 92.1% | 91.6% | 88.6% | 88.9% | 89.8% | 86.3% | 90.7% | 91.1% |
| Operating Expenses | ||||||||
| Research & Development | $13.1M | $7.5M | $10.9M | $8.4M | $7.4M | $5.7M | $8.1M | $3.0M |
| SG&A Expense | $23.5M | $22.0M | $29.3M | $26.2M | $26.0M | $20.3M | $37.0M | $42.4M |
| Operating Income | $46.3M | $41.4M | $33.2M | $29.7M | $20.1M | $21.8M | $-1.7M | $11.7M |
| Operating Margin | 55.7% | 53.3% | 43.1% | 40.5% | 28.7% | 35.0% | -2.8% | 17.3% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $48.8M | $43.9M | $35.7M | $32.0M | $22.2M | $24.3M | $1.2M | $14.8M |
| Income Tax Expense | $11.4M | $9.6M | $-175.1M | $411.0K | $643.0K | $1.0M | $-256.0K | $457.0K |
| Net Income | $37.4M | $34.4M | $210.8M | $31.6M | $21.5M | $23.3M | $1.4M | $14.4M |
| Net Margin | 45.0% | 44.2% | 273.4% | 42.9% | 30.7% | 37.4% | 2.4% | 21.2% |
| EPS (Basic) | $0.29 | $0.26 | $1.60 | $0.24 | $0.16 | $0.17 | $0.01 | $0.10 |
| EPS (Diluted) | $0.28 | $0.25 | $1.53 | $0.23 | $0.16 | $0.16 | $0.01 | $0.10 |
| Shares Outstanding (Basic) | 130.1M | 132.4M | 134.4M | 131.8M | 134.9M | 138.9M | 143.1M | 143.1M |
| Shares Outstanding (Diluted) | 133.5M | 137.6M | 138.7M | 136.0M | 137.5M | 143.2M | 146.2M | 145.7M |
| Dividends Per Share | — | — | — | — | — | — | — | — |